A closer look at MenoPulse’s launch, preliminary symptom findings and the questions that separate sexual-wellness claims from menopause treatment evidence.
Lovehoney Group launched its hormone-free MenoPulse device through SheHerMe, according to Longevity.Technology. The launch coverage reported UK availability through more than 250 Boots stores and online. The broader category also received attention from HealthyWomen, which published “Menopause Tech Is Getting Smarter About the Symptoms Women Live With” on October 15, 2026.
The MenoPulse report brings together a retail launch and preliminary company-related symptom data. Those deserve separate consideration. A product’s availability tells readers where it was being sold. Its research needs to answer a different question: what evidence supports the health claims attached to it?
For adults weighing menopause-related products, that distinction matters more than whether the technology sounds promising. The useful task is to identify what was studied before deciding how much weight to give the results.
Longevity.Technology describes MenoPulse as a hormone-free device using targeted clitoral air-pulse stimulation. Its launch coverage discusses a company-related user study involving 66 menopausal women over four weeks. Those details establish the reported group size and study period.
The central outcome discussed in the coverage was improvement in menopause symptoms. That is different from testing a narrowly defined physiological outcome. A symptom report concerns what participants experienced, while a physiological measure concerns a particular bodily process. The distinction becomes important when different kinds of research appear in the same product story.
The article also discusses earlier research involving sexual activity and autonomic-function measures. That background study and the MenoPulse user study are separate pieces of evidence. They should be read separately before considering whether they support a shared explanation.
For now, the clearest description is a short user study reported alongside a product launch. Keeping that description intact helps readers avoid assuming a more detailed research design than the coverage provides.
The company-related user-study reporting described symptom improvement in 92.9% of participants. That figure should remain attached to its source and setting: a preliminary finding presented in launch coverage. It is not an independently confirmed treatment success rate.
A percentage reporting improvement and the size of that improvement are different kinds of information. The first describes how many people were said to have experienced a change. The second would describe how substantial that change was. A headline percentage should not blur those questions together.
Separately, the article reported that symptom levels were lowest during periods of regular sexual activity, particularly when orgasm occurred. This was another finding discussed in the coverage. It should not be silently converted into a result specifically caused by MenoPulse.
The retail information was more straightforward. Reported availability through Boots placed the product in mainstream retail as well as the sexual-wellness category. That is relevant to consumer access and visibility, rather than to the strength of the symptom evidence.
Longevity.Technology also reported that SheHerMe planned a symptom-tracking and recommendation app and further products in 2027. These were plans for a broader product offering. They were not additional results from the user study or independent validation of its findings.
The launch article characterizes the reported result as an “interesting signal” rather than an established treatment effect. Its missing study details are central to that assessment.
Three questions remain especially important:
The article also raises the possibility that symptom tracking or increased attention to symptoms could influence reported outcomes. These are alternative explanations to consider when interpreting a user report. The available description does not separate their contribution from any effect of the device itself.
Generalizability is another concern. A finding from the reported participant group should not automatically be applied to every person experiencing menopause. The coverage does not supply enough information to judge how well the results would transfer across different symptom patterns or personal health circumstances.
There is also a distinction between immediate lubrication associated with arousal and longer-term genitourinary symptoms linked to estrogen-related tissue changes. The article describes a physiological rationale for the former. Whether repeated device use changes the latter remains unresolved.
Taken together, these gaps mean the coverage does not establish that MenoPulse caused the reported symptom improvements. The available sources also do not establish its safety or effectiveness for particular medical conditions. Being hormone-free describes the product’s approach, not its suitability for an individual.
The related research discussed in the launch article includes a 2022 observational study of healthy menopausal women. Its authors reported an association between sexual activity and heart rate variability, or HRV. This provided physiological context involving autonomic-function measures.
However, that study assessed penile-vaginal intercourse rather than clitoral air-pulse stimulation. Its observational design established an association, not that sexual activity caused the HRV differences. It was neither a clinical trial of MenoPulse nor evidence that this device treats menopause symptoms.
The comparison is useful because it shows why different outcomes need different evidence. An autonomic-function measure and a participant’s report of symptom relief are not interchangeable. Finding a relationship involving one does not supply a missing result for the other.
Likewise, physiological plausibility and clinical evidence serve different purposes. A plausible explanation can help researchers form a question worth testing. Evidence about a particular product must then address that product and the outcomes being claimed.
This is the appropriate place for the earlier study in the MenoPulse story: background that helps explain the research interest. It should not carry the weight of a product-specific efficacy study.
The practical starting point is to distinguish interest in a sexual-wellness product from expectations of a menopause treatment. The evidence supports describing MenoPulse as the former, accompanied by preliminary company-reported symptom data. That gives readers a clearer basis for evaluating the offer without dismissing sexual wellbeing as unimportant.
A useful consumer decision begins with the claim itself. “Hormone-free” identifies an approach. “Available through a familiar retailer” identifies access. “Associated with reported improvement” identifies an observation. These statements do different jobs and should not be treated as interchangeable assurances.
The same distinction applies to the concern a reader hopes to understand. A question about sexual interest is not identical to a question about physical comfort. Uncertainty about arousal is not the same as uncertainty about a broader menopause symptom. Keeping the concern specific makes the product claim easier to assess.
Sexential’s discussion of physical comfort and changes in sexual interest offers related context for making those distinctions. Its guide to changing sexual needs during perimenopause provides a broader educational starting point. Neither requires reducing sexual wellbeing to one symptom or one product.
For a healthcare conversation, the useful material is the original claim and the particular concern behind it. Bringing both keeps a discussion focused on whether the evidence addresses that concern. Decisions involving symptoms or suitability for a medical condition belong in an individual discussion with a qualified healthcare professional.
There is no need to turn the reported association with sexual activity into a personal target. Sexual activity and orgasm should not become assignments for managing menopause. An individual’s preferences and comfort do not need to meet a study’s pattern to be taken seriously.
Nor does evaluating the evidence require an all-or-nothing verdict on the product. Someone can find a sexual-wellness device interesting while reserving judgment about its medical claims. Clear boundaries around those claims make room for curiosity without asking preliminary research to provide certainty.
Sexual wellbeing deserves clear evidence and room for individual choice.
Judging a menopause device’s symptom claims requires separating product information from health evidence, a distinction Sexential supports through mature sexual wellbeing education. Readers aged 35 to 65 can use that context to better understand influences on sexual function, with biology and relationships considered together rather than reduced to a product promise.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
A report on a student survey links attention with men’s sexual satisfaction. Here’s the evidence, its limits and the practical context for midlife.
A new report puts men’s midlife testosterone changes in context, with guidance on assessment, partner conversations and fertility considerations.
The Menopause Society’s 2026 program places lifestyle, sleep and sexual health together. Here is what the agenda and partner research actually report.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
